Restoration of Patency to Central Airways Occluded by Malignant Endobronchial Tumors Using Intratumoral Injection of XXXX .

@entity1 @entity4153 @entity5 @entity957 @entity2 @entity900 @entity189 @entity4202 @entity420 @entity1224
RATIONALE: Malignant @entity1224 is commonly found in @entity1 with @entity2 and is associated with significant morbidity and mortality. Relieving @entity5 may improve symptoms, quality of life, and life expectancy. OBJECTIVES: The objective of this study was to analyze our experience with bronchoscopic endobronchial intratumoral injection of @entity900 for @entity1224 . METHODS: We conducted a retrospective analysis of @entity1 with @entity1224 treated with bronchoscopic intratumoral injection of @entity900 . @entity1 characteristics, histology, degree of @entity1224 , procedural methods, treatment cycles, performance status, and therapeutic outcomes were evaluated. @entity5 response was analyzed based on bronchoscopic measurements performed on completion the of final treatment session. Adverse events and overall survival were abstracted. MEASUREMENTS AND MAIN RESULTS: Between January 2009 and September 2014, 22 @entity1 (10 @entity1 , 12 @entity1 ; mean age        SD, 64.4        9.5 yr) were treated with one to four injections of 40 mg of @entity900 mixed in 40 ml of 0.9% @entity4202 . Treatments were completed 1 week apart. The primary etiologies of @entity1224 included @entity957 (n   =   11), @entity420 (n   =   6), @entity4153 (n   =   2), large cell undifferentiated @entity189 (n   =   1), and metastatic @entity5 (n   =   2). Twenty-one of 22 @entity1 were evaluable for response. The majority of @entity1 (15/21, 71.4%) responded to therapy, defined as greater than 50% relative reduction in obstruction from baseline. Treatment response was obtained regardless of @entity5 histology, concurrent systemic therapy, number of treatment cycles administered, performance status, or use of additional ablative interventions. Responders had significantly improved overall survival as compared with nonresponders, although the difference was small. Severe treatment-related side effects or complications were not observed. CONCLUSIONS: Subject to the limitations of a single-center retrospective study and a subjective primary outcome measure, we have demonstrated the feasibility of improving the patency of central airways that are largely or completely occluded by @entity5 using intraluminal injection of @entity900 . Additional longer-term, larger-scale safety and comparative effectiveness studies of this palliative treatment modality are warranted.
